MODEL VERDICT
Inhibrx Biosciences, Inc. (INBX) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Feb 28, 2026 | MODERATE | 0.55 | $74.13 | CURRENT | — |
| Feb 21, 2026 | MODERATE | 0.55 | $78.64 | CURRENT | — |
| Feb 14, 2026 | MODERATE | 0.55 | $75.80 | CURRENT | — |
| Feb 11, 2026 | MODERATE | 0.55 | $83.30 | CURRENT | — |
| Jan 11, 2026 | MODERATE | 0.67 | $72.86 | Pending | +18.7% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Industry Median P/E 48 industry peers | $2541.95 | +3329.0% | 15% | A | Peer Data |
| EV To Revenue 130 industry peers | $10.90 | -85.3% | 4% | B | Data |
| Price / Sales 130 industry peers | $0.94 | -98.7% | 3% | B | Model Driven |
| Earnings Yield 47 industry peers | $3026.48 | +3982.7% | 2% | B | Data |
| Weighted Output Blended model output | $1631.17 | +2100.4% | 100% | 51 | SIGNIFICANTLY UNDERVALUED |
| EPS Growth ↓ | P/E Multiple → | 4× (Current) | 4× | 4× | 4× | 5× |
|---|---|---|---|---|---|
| Bear Case (4%) | $485 | $485 | $485 | $485 | $606 |
| Conservative (7%) | $497 | $497 | $497 | $497 | $621 |
| Base Case (10.0%) | $513 | $513 | $513 | $513 | $641 |
| Bull Case (14%) | $529 | $529 | $529 | $529 | $662 |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 20.52 | 17.02 | 1.67 | 41.17 | 15.88 |
| P/B Ratio | 20.52 | 17.02 | 1.67 | 41.17 | 15.88 |
| P/S Ratio | 571.69 | 450.85 | 65.03 | 1114.64 | 463.68 |
Based on our peer multiples analysis with 9 valuation metrics, the model estimates INBX's fair value at $1631.17 vs the current price of $74.13, implying +2100.4% upside potential. Model verdict: Significantly Undervalued. Confidence: 51/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $1631.17 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%).
INBX's current P/E of 0.6x compares to the industry median of 21.8x (48 peers in the group). This represents a -97.1% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
5 analysts cover INBX with a consensus rating of Buy. The consensus price target is N/A (range: N/A — N/A), implying N/A upside from the current price. Grade breakdown: Strong Buy (0), Buy (3), Hold (2), Sell (0), Strong Sell (0).
The model confidence score is 51/100, based on: data completeness (3), peer quality (25), historical depth (16), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for INBX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.